David Webster, Body Vision Medical - AI-Driven Intraoperative CT Imaging | LSI USA '24

David Webster  0:05  
So today I'm going to talk to you a little bit about AI. I'm sure you've heard a little bit about it today, you're going to hear more about it as time goes on. I think Elon Musk made this quote recently about where AI is heading. And it is moving forward very fast, a lot faster than anything we've ever seen before, because it learns from itself. I think that med tech that doesn't have it or isn't incorporating it in the next three to five years is going to be it's going to be problematic. It's moving very, very quickly. So today, I'm here to talk to you about AI driven image guided navigation in lung cancer. So we have a problem with lung cancer. I think we all know what the problem is. First of all, it's quite late, the later it's caught. The greater the deaths by the by the cancer. It's interesting, because you hear prostate, you hear breast you hear colorectal all about that. But when you add all those up, they don't equal the number of people dying from lung cancer. So it remains a problem. That's the first problem. The second problem is, even though this is happening, our ability to detect it, and to diagnose it is also problematic. So if you look at this chart here, breast cancer has the highest detection, why people are compliant with breast cancer screening, we're working and we're getting getting better. But the numbers that we're dealing with today, the numbers that we're barely dealing with today, for lung cancer, less than 6% of people who can have lung cancer detection actually get it. The good news is that number is going to go up. The bad news is when that number goes up, we have another problem. And that problem is how do we diagnose? So even though right now a million of the of the 15 million are being detected 250,000 are being diagnosed. So there's a big problem there. So when a nodule is detected, how is that handled? Two things are not suspicious binding, not suspicious finding, they send you home and they observe. They say let's see where this thing goes. If it gets bigger, we'll deal with it. For suspicious finding you have two options. The first option is what's called CT guided T TNA it's very accurate. It's it's not that expensive, but it's problematic because in about 25 to 30% of those patients, they have pneumothorax, the lung collapses and they're already compromised. So what we're doing is we're moving towards a less invasive solution, which is airway bronchoscopy or a bronchoscopy biopsy, that's where you go down the airway, you weave yourself to the lesion. And when you get to the lesion, we biopsy the lesion, less invasive low risk, but very, very inaccurate. So we've been at it for a long time airway brown costs could be it started with the bronchoscope problem with the bronchoscope is less than 50% diagnostic yield because that means in less than 50% of the cases, they get to the lesion right and they get an accurate biopsy. So what was then invented Electromatic electromagnetic navigation Veyron Super dimension Illuma site, you can see the diagnostic yield got better, but not dramatically better. 70%. So what entered the market then, robotic platforms. The interesting thing about the robotic platforms is all things being equal, their diagnostic yield is about the same as electromagnetic navigation. Now what these two platforms did is they drove up the price. So the cost of a bronchoscopy airway bronchoscopy is very low. When you add the navigation and the robot platforms, they use proprietary consumables, so it drives the price up the differentiator, driving the numbers way up, is intraoperative 3d imaging. And there's sort of two ways you can get that one is a cone beam CT, which is a multimillion dollar room, and another one is a 3d car. In all those cases, the problem, you have two challenges. The first challenge is the first one CT to body divergence. That means the preoperative CT that you're using to guide themselves to the lesion is inherently inaccurate when use inner operatively. So they routinely find themselves way off from where the lesion needs to be. The second challenge is confirmation and lesion. And if you can imagine this is a screenshot from one of the new robots where the tool was almost two centimeters away from the lesion and it becomes very difficult first navigating to the lesion. And secondly, when you think you're at the lesion, getting the tool and lesion and getting the biopsy you have it's very problematic becomes more problematic when you have a bronchoscope it gets a little bit better with electromagnetic gait navigation a little bit better with the robot. So I'm going to play you a quick video that shows you what our technology does the body vision technology and how it works. We are FDA cleared. We are CE mark and we do Have you MDR so we're in full commercial phase right now, today, it is challenging to diagnose pulmonary nodules, because you are unable to see exactly where the lesion is during the procedure. Body visions game changing technology provides real time inter Operative 3d imaging using any conventional CR while allowing you to see the actual lesion and lesion location during the procedure. Precisely navigate to the lesion under augmented fluoroscopy visually confirm tool and lesion in multiple 3d planes prior to biopsy. And then under augmented fluoroscopy, biopsy with confidence knowing that you see in real time that you are obtaining tissue samples from within the lesion. Clinical studies have demonstrated that tool and lesion confirmation prior to biopsy can result in a diagnostic yield approaching if not exceeding 90% Lung vision, a breakthrough innovation in lung cancer diagnostics,

David Webster  6:01  
the AI is taking images 2d images, a very short span of 2d images from a 3d car. And it's creating three image sets for the doctor. First of all, is an axial sagittal and coronal view, fused with the pre op CT doing the automatic correction of the lesion. Second is a 3d view of the lesion. So once the tool is at the lesion, you confirm that it's embedded in the lesion. And third, most importantly, is it setting the quickest path to the lesion. And it's allowing the doctor with very low dose scans to guide themselves with images to the lesion. So we're taking this and we're giving you this, we're taking the most widely available imaging device in the operating room, and we're turning it into the top of the line Cone Beam CT. And I think that's what you're going to see ai do in this revolution coming up, especially in imaging is taking existing imaging modalities and improving the performance of them and giving you more and more capability about what exists, thus reducing price. So what are the results, you can take the lung vision system with any robotic navigation platform in any CRM, and we're delivering 94% and higher diagnostic yield. More importantly, we're taking any bronchoscope in any CRM, and we're dealing at 89 and higher percent diagnostic yield. So where most of the world can afford the top solution, we're giving that same superior diagnostic yield to what the whole world has. So where are we as a company, in the last 18 months, we've opened 36 countries most recently reopened, China, the rest of the world has no solutions. The robots aren't there. So we're bringing this to the rest of the world and to the US. We've seen very strong growth by the end of 2024, we'll add another 67 systems worldwide, were validated with all the major imaging platforms. So any car made by the big companies were validated with, and we're making great strides with our software. So we're moving very fast with a small team. What's next for us from diagnosis to treatment, the future of lung cancer is targeted therapeutics, we're on that because of our accuracy. Because of our speed, we'll be helping to deliver targeted therapeutics to the rest of the world. In addition, here's what we know about the AI, we can teach it to navigate to other soft tissue. So continuing to improve the performance of C arms and give that soft tissue imaging that the whole world needs but can't afford with CT or with Cone Beam CT. So if you'd like to learn more, you can click on the QR code. And you can learn more about the company and I'll be here for the next couple of days. Happy to answer questions. But we're in a we're in a round right now to increase our commercialization. Thank you